

NRG-GU012: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of renal cell cancer with positive lymph nodes that can't be removed or metastasis to another area - not recommended for or refused immediate nephrectomy
- must agree to use a highly effective contraception while on study drug and for 6 months following the last dose of study drug - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- untreated or unstable brain metastases - prior radiotherapy to the kidney - systemic therapy for metastatic renal cell carcinoma (RCC) that was initiated > 90 days before starting the study - women who are pregnant or breastfeeding -see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

Clinics and Surgery Center (CSC), Kidney Cancer, Metastatic Renal Cell Carcinoma

More Information

Description: The primary purpose of this study is to find out if adding a highly focused form of radiation therapy (called SABR) to the main kidney tumor, along with immunotherapy, helps people with advanced kidney cancer live longer or do better than using immunotherapy by itself.

Study Contact: Ian Okazaki - okaza001@umn.edu

Principal Investigator: Ian Okazaki

Phase: PHASE2

IRB Number: STUDY00025313

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.